SOST and obesity disorder: While no difference in serum sclerostin was documented in obese as compared to control women [35], serum sclerostin was found to be negatively associated with insulin sensitivity in obese but not lean subjects, suggesting a potential role for the Wnt/β-catenin pathway in regulating insulin sensitivity in obesity [36].